MaaT Pharma (EURONEXT: MAAT), a French clinical-stage biotech, is revolutionizing the field of cancer treatment with its pioneering Microbiome Ecosystem TherapiesTM (MET). The Company has earned the attention of Kepler Cheuvreux, which has begun providing coverage of MaaT Pharma’s stock. MaaT Pharma is committed to improving survival outcomes for cancer patients around the world with its cutting-edge MET treatments.
Kepler Cheuvreux is starting coverage of MaaT Pharma with a Buy recommendation, based on their research report titled “The Microbiome Revolution”. Don’t miss out on this opportunity to capitalize on the potential of this innovative company!
MaaT Pharma’s visibility among French and international institutional investors is set to rise, with the addition of this new coverage. Already supported by KBC Securities, Kempen and Portzamparc/Groupe BNP Paribas, MaaT Pharma’s presence in the investment landscape will be further enhanced.
About MaaT Pharma
MaaT Pharma is on a mission to restore patient-microbiome symbiosis and revolutionize cancer and graft-versus-host disease (GvHD) treatments. To this end, the clinical stage biotechnology company launched a Phase 3 clinical trial in March 2022, following a successful proof of concept in a Phase 2 trial. MaaT Pharma’s cutting-edge gutPrint® platform supports the development and expansion of its pipeline by uncovering novel disease targets, assessing drug candidates, and identifying biomarkers associated with microbiome-related conditions.
MaaT Pharma is revolutionizing the healthcare industry with its groundbreaking Microbiome Ecosystem Therapies. These therapies are manufactured in accordance with strict cGMP and quality control standards to ensure safe and effective delivery of the full diversity of the microbiome, available in both liquid and oral formulations. With the support of world-renowned scientists and strong relationships with regulators, MaaT Pharma is paving the way for the successful integration of microbiome therapies into clinical practice.
MaaT Pharma has become the latest addition to the Euronext Paris stock exchange, trading under the ticker symbol MAAT. Investing in the French pharmaceutical giant is now possible through the world’s oldest stock exchange.